Drug Details

General Information of the Drug (ID: DR6421)
Name
Fluvoxamine
Synonyms
fluvoxamine; 54739-18-3; Fluvoxaminum; Fluvoxamina; (Z)-Fluvoxamine; UNII-O4L1XPO44W; Fluvoxaminum [INN-Latin]; Fluvoxamina [INN-Spanish]; 2-[(E)-[5-methoxy-1-[4-(trifluoromethyl)phenyl]pentylidene]amino]oxyethanamine; CHEMBL814; O4L1XPO44W; CHEBI:5138; Fluvoxamine [INN:BAN]; (1E)-5-methoxy-1-[4-(trifluoromethyl)phenyl]pentan-1-one O-(2-aminoethyl)oxime; DSSTox_CID_24002; DSSTox_RID_80097; DSSTox_GSID_44002; (E)-5-Methoxy-1-(4-(trifluoromethyl)phenyl)-pentan-1-one O-(2-aminoethyl) oxime; 1-Pentanone, 5-methoxy-1-(4-(trifluoromethyl)phenyl)-, O-(2-aminoethyl)oxime, (E)-; Fluvoxamine (INN); CAS-54739-18-3; C15H21F3N2O2; N06AB08; (E)-5-Methoxy-1-(4-(trifluoromethyl)phenyl)pentan-1-one O-(2-aminoethyl) oxime; NCGC00018193-06; FVX; Prestwick2_000995; Prestwick3_000995; Lopac0_000495; SCHEMBL33983; BSPBio_001089; BIDD:GT0609; BPBio1_001199; DTXSID2044002; 2-[(Z)-[5-methoxy-1-[4-(trifluoromethyl)phenyl]pentylidene]amino]oxyethanamine; HY-B0103; Tox21_110837; BDBM50028091; ZINC12466082; AKOS016003882; Tox21_110837_1; AC-1679; CCG-204586; CS-1840; DB00176; SDCCGSBI-0050479.P002; 2-[({(1E)-5-methoxy-1-[4-(trifluoromethyl)phenyl]pentylidene}amino)oxy]ethanamine; NCGC00018193-04; NCGC00018193-05; NCGC00018193-07; NCGC00018193-08; NCGC00018193-11; NCGC00018193-21; NCGC00021870-04; NCGC00021870-05; AS-15332; O893; AB0016707; AB00514702; 39F183; C07571; D07984; AB00513735_05; AB00513735_06; A830353; BRD-K53517854-050-03-2; Q27259474; (E)-5-Methoxy-4'-(trifluormethyl)valerophenon-O-(2-aminoethyl)oxim; (2-aminoethoxy)({5-methoxy-1-[4-(trifluoromethyl)phenyl]pentylidene})amine; 5-methoxy-1-[4-(trifluoromethyl)phenyl]-1-pentanone O-(2-aminoethyl)oxime; 1-Pentanone, 5-methoxy-1-[4-(trifluoromethyl)phenyl]-,O-(2-aminoethyl)oxime, (1E)-
    Click to Show/Hide
Molecular Type
Small molecule
Disease Depression [ICD-11: 6A70-6A71] Approved [1]
Structure
Click to Download Mol
2D MOL

3D MOL

    Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product
Formula
C15H21F3N2O2
PubChem CID
5324346
Canonical SMILES
COCCCCC(=NOCCN)C1=CC=C(C=C1)C(F)(F)F
InChI
1S/C15H21F3N2O2/c1-21-10-3-2-4-14(20-22-11-9-19)12-5-7-13(8-6-12)15(16,17)18/h5-8H,2-4,9-11,19H2,1H3/b20-14+
InChIKey
CJOFXWAVKWHTFT-XSFVSMFZSA-N
CAS Number
CAS 54739-18-3
ChEBI ID
CHEBI:5138
TTD Drug ID
D03HFG
DrugBank ID
DB00176
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally
    α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug
          Tropisetron      Homo sapiens     Click to Show/Hide the Molecular Data of This NP
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [2]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    Biological
                    Regulation		 Down-regulation 5-HT content
                    In-vivo Model Clinical Trial
                    Experimental
                    Result(s)		 This trial showed a significant efficacy for tropisetron over placebo in treatment of obsessive-compulsive disorder symptoms when added to fluvoxamine.
Target and Pathway
Target(s) Serotonin transporter (SERT)  Molecule Info  [3]
KEGG Pathway Serotonergic synapse Click to Show/Hide
NetPath Pathway TCR Signaling Pathway Click to Show/Hide
Panther Pathway 5HT1 type receptor mediated signaling pathway Click to Show/Hide
2 5HT2 type receptor mediated signaling pathway
3 5HT3 type receptor mediated signaling pathway
4 5HT4 type receptor mediated signaling pathway
WikiPathways Monoamine Transport Click to Show/Hide
2 SIDS Susceptibility Pathways
3 NRF2 pathway
4 Synaptic Vesicle Pathway
5 Serotonin Transporter Activity
References
Reference 1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7189).
Reference 2 Fluvoxamine combination therapy with tropisetron for obsessive-compulsive disorder patients: A placebo-controlled, randomized clinical trial. J Psychopharmacol. 2019 Nov;33(11):1407-1414.
Reference 3 Changes of functional MRI findings in a patient whose pathological gambling improved with fluvoxamine. Yonsei Med J. 2009 Jun 30;50(3):441-4.
 Download Picture         KEGG Link